Swedish Orphan Biovitrum (OTCMKTS:BIOVF) Reaches New 52-Week High – What’s Next?

Swedish Orphan Biovitrum (OTCMKTS:BIOVF) shares reached a new 52-week high during trading on Wednesday . The company traded as high as $37.00 and last traded at $37.00, with a volume of 400 shares. The stock had previously closed at $35.25.

Analyst Upgrades and Downgrades

Separately, Deutsche Bank Aktiengesellschaft raised Swedish Orphan Biovitrum from a “sell” rating to a “buy” rating in a research note on Monday, November 3rd. One investment analyst has rated the stock with a Buy rating, Based on data from MarketBeat, the company presently has an average rating of “Buy”.

Swedish Orphan Biovitrum Stock Performance

The company has a quick ratio of 0.69, a current ratio of 1.02 and a debt-to-equity ratio of 0.24. The stock has a fifty day moving average price of $35.24 and a two-hundred day moving average price of $32.21. The company has a market capitalization of $13.17 billion, a price-to-earnings ratio of -528.57 and a beta of 0.37.

Swedish Orphan Biovitrum (OTCMKTS:BIOVF) last posted its quarterly earnings data on Monday, October 20th. The company reported $0.64 EPS for the quarter, beating analysts’ consensus estimates of $0.49 by $0.15. The business had revenue of $826.53 million for the quarter, compared to analyst estimates of $818.86 million. Swedish Orphan Biovitrum had a positive return on equity of 13.66% and a negative net margin of 0.97%.

Swedish Orphan Biovitrum Company Profile

Swedish Orphan Biovitrum AB (publ), commonly known as Sobi, is a Stockholm‐based biopharmaceutical company specializing in the development, manufacturing and commercialization of treatments for rare diseases. Formed in 2010 through the merger of Swedish Orphan International AB (established 1985) and Biovitrum AB, the company focuses on high‐value therapies in hematology, immunology, oncology and genetic/metabolic disorders. Sobi’s strategy centers on building a global specialty care portfolio by in‐licensing, acquiring and internally developing innovative products aimed at small patient populations with significant unmet needs.

The company’s marketed portfolio includes recombinant clotting factor therapies such as Elocta (rFVIIIFc) and Alprolix (rFIXFc) for hemophilia A and B, respectively; Ruconest, a recombinant human C1 esterase inhibitor for hereditary angioedema; and Kineret (anakinra) for certain auto‐inflammatory conditions.